And using tDCS for patients with depression with type I or II bipolar disorder, not only was the patient’s higher baseline IL-6 concentration associated with therapeutic efficacy, but the patient’s plasma IL-8 concentration also decreased significantly after treatment [21]. Here, CXCL8 is linked to depressive symptom measurement.